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Abstract
Aim Type 1 diabetes is the most common chronic metabolic disease in childhood. Often diagnosis comes with acutely life-
threatening ketoacidosis and requires hospitalization. To avoid this, early detection of children at a pre-symptomatic stage is
worthwhile. This task is met by a population-based screening in Bavaria, Germany – the Fr1da study. Here, we aim to evaluate
the study concept, feasibility and medical evidence of the Fr1da study.
Methods 308 pediatricians, 16 diabetes care centers and participating families were asked to evaluate the Fr1da study by
completing questionnaires assessing study concept and feasibility, educational program and study organization. The assessment
was done anonymously. In order to evaluate the effectiveness of the training the parents had to answer questionnaires to assess
their knowledge about diabetes.
Results 48% of pediatricians and 56% of pediatric diabetes care centers filled out the questionnaire. The majority positively
judged the collaboration with the Fr1da coordinating center and the feasibility to integrate the project into daily routine. Medical
evidence of the screening was recognized and most of the respondents endorsed the screening to be permanently integrated into
standard care-program. The majority of parents would recommend the study to other parents with young children since they were
satisfied with the collaboration with pediatricians, diabetes care centers and the coordinating center. Quality control of the
educational program revealed good understanding of the teaching content.
Conclusion The Fr1da study received high acceptance and recognition by both, health care providers and participating families,
and demonstrated sustainable success with the developed educational program.
Keywords Public health . Children . Endocrine disorders, incl. Diabetes . Prevention
Introduction
Type 1 diabetes is one of themost common chronic diseases of
childhood with a prevalence of 0.3–0.6% (Ziegler and Nepom
2010; Ehehalt et al. 2012; International Diabetes Federation
2013; Bonifacio et al. 2017). Symptomatic disease onset is
often diagnosed by blood glucose measurements at the acute
life-threatening onset of the disease. Acute disease onset often
requires hospitalization and occurs by severe metabolic de-
compensation (Ziegler and Nepom 2010; Bonifacio et al.
2017). The management of metabolic decompensation and
the adaption of the families to the disease and its treatment
are major personal and financial burdens (International
Diabetes Federation 2013). Symptomatic type 1 diabetes is
preceded by distinct identifiable stages of pre-symptomatic
beta cell autoimmunity and glucose intolerance (Ziegler et al.
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2013; Insel et al. 2015a, b). Stage 1 is defined as the presence
of two or more beta cell autoantibodies with normoglycemia,
and stage 2 as the presence of two or more beta cell autoanti-
bodies with dysglycemia (glucose intolerance). Diagnosis of
type 1 diabetes in an early pre-symptomatic stage can help to
prevent acute disease onset, and reduce the prevalence of met-
abolic decompensation and associated hospitalization (Elding
Larsson et al. 2011; Winkler et al. 2012). It may also open the
path to population-based disease prevention.
The Fr1da study explored this concept as a model public
health project in Bavaria, Germany, and introduced general
population-based detection of early pre-symptomatic stages
of type 1 diabetes at well child visits (U-Untersuchung) to
detect a high proportion of children who will develop symp-
tomatic type 1 diabetes (Ziegler et al. 2013; Insel et al. 2015b;
Raab et al. 2016). The Fr1da study was launched in 2015. The
study is directed by the Helmholtz Center Munich in cooper-
ation with the professional association of primary care pedia-
tricians, pediatric diabetes care centers and the ministry of
health of Bavaria. After 30 months of participation, the prima-
ry care pediatricians and pediatric diabetes care centers were
asked to evaluate the Fr1da study concept, assess the project
feasibility, and judge the organizational infrastructure.
Additionally, parents with a child diagnosed with pre-
symptomatic type 1 diabetes were asked to evaluate the
Fr1da study. Here we present the results of this self-evalua-
tion. To assess the effectiveness of an educational training
about pre-symptomatic type 1 diabetes, which is provided to
the parents, their knowledge about type 1 diabetes was tested.
Methods
Fr1da study design
In the Fr1da study, children aged 2–5 years in Bavaria,
Germany, are screened for the presence of multiple beta cell
autoantibodies (pre-symptomatic stages of type 1 diabetes)
(Raab et al. 2016). A total of 74,990 children participated in
the Fr1da screening by March 2018. Screening is accom-
plished by primary care pediatricians or physicians. Beta cell
autoantibodies are measured in capillary blood samples using
the 3 Screen Islet Cell Autoantibody ELISA (RSR Ltd.,
Cardiff, UK) (Ziegler et al. 2016). Samples with ELISA re-
sults >97.5th centile are retested using reference radiobinding
assays (Amoroso et al. 2016). A venous blood sample is ob-
tained to confirm the autoantibody status of children with at
least two positive autoantibodies against insulin, GAD, IA-2
or ZnT8. Children with confirmed positive multiple beta cell
autoantibodies are diagnosed with pre-symptomatic type 1
diabetes.
These children and their parents are invited to participate in
an education and counseling program and metabolic staging
by oral glucose tolerance test at the local pediatric diabetes
care center. Diagnosis-related depression and anxiety are
assessed. Details of the study protocol have been previously
published (Raab et al. 2016). The study is approved by the
Ethical Committee of the Technical University, Munich,
Germany (No. 70/14).
Fr1da coordinating center
The Fr1da coordinating center at the Helmholtz Center
Munich is providing information and consent material, supply
material (capillary and venous blood tubes, shipping sup-
plies), and is responsible for autoantibody diagnostics and
result reporting to the primary care pediatricians as well as
to the pediatric diabetes care centers. A free telephone hotline
is provided to physicians and families for questions and con-
cerns. The coordinating center reimburses to primary care
pediatricians and to pediatric diabetes care centers for ex-
penses regarding consent processes, blood draws, metabolic
staging, education, and psychological assessment, respective-
ly. With regard to families participating in the Fr1da study, the
coordinating center provides each family with a study assis-
tant who is responsible for appointments, assessment of urine
and/or blood glucose monitoring at home and is the primary
contact person for study and diabetes related questions.
In collaboration with the Department of Medical
Psychology, Hannover Medical School, Hannover, Germany
the constantly evaluation of the Fr1da study by parents is
performed.
Primary care pediatricians
Primary care pediatricians are responsible for obtaining in-
formed consent to participate in the Fr1da study, and for
collecting capillary blood into 200 μl tubes. Samples are
stored in a refrigerator and returnedweekly to the coordinating
center. Additionally, the pediatrician instructs the family to
complete a 1-page questionnaire covering demographic data,
type 1 diabetes family history and environmental exposures.
The pediatrician may be asked to collect a venous blood sam-
ple for confirmation of positive autoantibody measurements.
If a child is diagnosed with pre-symptomatic type 1 diabetes,
the pediatrician is informed (phone call and written result let-
ter) of the diagnosis and the autoantibody status, and then
informs the family.
Pediatric diabetes care centers
Pediatric diabetes care centers are responsible for education and
counselling of parents of children with pre-symptomatic type 1
diabetes. The educational program instructs the parents about
urine and blood glucose monitoring, symptoms of hyperglyce-
mia, pathogenesis of type 1 diabetes, insulin action, and normal
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and pathological blood glucose levels. Additionally, they per-
form metabolic staging by oral glucose tolerance test (OGTT)
and HbA1c to assess glucose tolerance (normal, impaired or
pathological). For all children with pre-symptomatic type 1
diabetes, a monitoring plan is implemented, which includes
visits to the pediatric diabetes care centers every three to six
months depending on the child’s glucose tolerance.
Evaluation of participation in the Fr1da study
Primary care pediatricians and pediatric diabetes care centers
were asked to evaluate the Fr1da study after 30 months of
participation using a 2-page questionnaire assessing study
concept, study feasibility, and study organization. It was sent
via a web-based Bavarian pediatric network (PaedNetz; http://
www.paednetz.de) to 308 primary care pediatricians; a second
2-page questionnaire assessing study concept, educational
program, and study organization was sent to 16 pediatric dia-
betes care centers (supplemental material). The assessment
was done anonymously. Parents of children diagnosed with
pre-symptomatic type 1 diabetes were asked to evaluate their
participation in the Fr1da study after receiving the diagnosis.
To determine the quality of the educational program, parents
were asked to attend a knowledge test immediately after the
training and six and twelve months later.
Results
Primary care pediatricians and pediatric diabetes care
centers
After screening of 63,000 children in the Fr1da study, 308
primary care pediatricians and 16 pediatric diabetes care centers
were asked to participate in this evaluation. 148 (48%) primary
care pediatricians and 9 (56%) pediatric diabetes care centers
responded and filled out the questionnaire. For each question,
five categories were possible (supplemental material).
Overall, the majority of primary care pediatricians and pe-
diatric diabetes care centers gave a very positive judgment
concerning the concept of the Fr1da screening and their par-
ticipation in the project. 90% of the primary care pediatricians
(Table 1; question 1) as well as 100% of pediatric diabetes care
centers (Table 3; question 10) endorsed the Fr1da screening
from a medical point of view. Furthermore, 84% of primary
care pediatricians (Table 1; question 2) judged the screening
for pre-symptomatic early stage of type 1 diabetes
very/somewhat useful for families including the opportunities
and burden involved. This assessment was shared by 78% of
pediatric diabetes care centers (Table 3; question 1). The pos-
itive judgement of participation in the Fr1da study was
reflected by the positive assessment of the collaboration with
the Fr1da coordinating center. Primary care pediatricians as Ta
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well as pediatric diabetes care centers were satisfied with the
information they received about the Fr1da study, the availabil-
ity of the coordinating center to answer questions and the
service provided by the coordinating center concerning mate-
rials and responses (Table 2; question 8–11 and Table 3; ques-
tion 5–8). This well attuned working together led to very
good/good possibility to integrate the Fr1da screening into
daily routine for 69% of primary care physicians (Table 1;
question 4). The majority of pediatric diabetes care centers,
which were responsible for initial training and metabolic stag-
ing of children diagnosed with pre-symptomatic type 1 diabe-
tes rated the amount of work concerning initial training, treat-
ment and long-term care less than for children diagnosed at a
symptomatic stage (Table 3; question 2–4). Overall, according
to 70% of primary care pediatricians (Table 1; question 3) it
would be very/somewhat useful to integrate the screening for
pre-symptomatic type 1 diabetes permanently into the stan-
dard screening and check-up program.
Parents
258 parents of 129 children diagnosedwith a pre-symptomatic
stage of type 1 diabetes were asked to evaluate the Fr1da study
six months after receiving the diagnosis. 170 (66%) parents
responded and filled out the 6 months questionnaire. For each
question, five categories of appreciation were given.
Overall, the participating parents gave a positive judgement
concerning their decision to participate in the Fr1da study.
84% of parents (Fig. 1, Suppl. Table 1, question 1) were very
satisfied/ satisfied that their child is participating in the Fr1da
study. 145 (85%) parents were very satisfied/satisfied with the
communication of the diagnosis of a pre-symptomatic stage of
type 1 diabetes by their primary care pediatrician (Fig. 1,
Suppl. Table 1, question 5). The educational training provided
by pediatric diabetes care centers was also mostly positively
judged (Fig. 1, Suppl. Table 1, question 6). The majority of
parents were also satisfied with the support they received from
the coordinating center. This included the opportunity to con-
tact someone with questions (Fig. 1, Suppl. Table 1, question
7), the organization of the Fr1da study (Fig. 1, Suppl. Table 1,
question 8) and the written information provided (Fig. 1,
Suppl. Table 1, question 9). Altogether, 80% of parents at
six months (Suppl. Table 1, question 2) assessed their decision
to participate in the Fr1da study as very good/good.
To determine the effectiveness of the educational training,
parents were asked to answer questions about type 1 diabetes
immediately after the training and six and twelve months later
(Fig. 2). 157 (55%) parents participated the test immediately
after the training, 156 (60%) parents after six months and 114
(62%) parents after twelvemonths. 80 to 90% of parents could
list at least three symptoms of acute hyperglycemia in children
(Suppl. Table 2, questions 1) initially, six and twelve months
after the training.
The knowledge about blood sugar values fasting and after a
meal (Suppl. Table 2, questions 2 and 3) increased during the
time of participation. Parents were introduced to blood sugar
measurements at their follow-up visits, especially if children
changed from normal to impaired glucose tolerance. For chil-
dren with normal glucose tolerance, urine glucose measure-
ments were recommended once a month. 50 to 60% of parents
knew which color indicated elevated glucose in the urine
using urine testing stix (Suppl. Table 2, question 4).
Discussion
The Fr1da study is one of the largest public health research
studies in diabetes engaging children and families, their pri-
mary care pediatricians, as well as diabetes clinical care cen-
ters under leadership of one central coordination center and
laboratory. Until evaluation, over 63,000 families participated
through their primary care physicians in the Fr1da study
Table 2 Evaluation of Fr1da screening by primary care pediatricians with at least one child diagnosed with pre-symptomatic type 1 diabetes
Primary care pediatricians – with at least one child diagnosed with pre-symptomatic type 1 diabetes (n = 49)
Rating very good n (%) good n (%) satisfactory n (%) poor n (%) very poor n (%) no response n (%)
8) How would you rate the information on
diagnosis provided by the coordinating center?
25 (51) 16 (33) 5 (10) 3 (6) 0 0
9) How would you rate the referral of the family
to a pediatric diabetes care center for training
and consultation?
21 (43) 15 (31) 7 (14) 2 (4) 0 4 (8)
10) How would you rate the support provided by
the coordinating center for the ongoing care of
the family and the child?
24 (49) 12 (24) 6 (12) 4 (8) 0 3 (6)
11) How would you rate the current support
provided by the pediatric diabetes care center
for the family and the child?
22 (45) 18 (37) 4 (8) 1 (2) 0 4 (8)
J Public Health (Berl.): From Theory to Practice (2019) 27:553–560 557
indicating that the Fr1da study concept was well accepted in
the population and medical community. As we think it is im-
portant to quantify the benefits of research in society early in
our project to be able to adjust our approach in case of subop-
timal results we asked participating primary care providers
and specialists as well as parents to evaluate the Fr1da public
health project after 30 months of implementation/operation.
The overall feedback was positive. In summary, the prelim-
inary evaluation demonstrated that the public health Fr1da
project reached the medical community and was well per-
ceived from primary care providers and specialists. The im-
plementation into daily routine was mostly considered feasi-
ble. The societal impact of an early diagnosis of type 1 diabe-
tes was recognized. The central organization was acknowl-
edged. The strength of our evaluation was that two different
professional groups as well as the patients were included into
the evaluation, and that the project was operating for a long
enough period before the evaluation was performed. The lim-
itations included the participation rate of less than 50%.
Several surveys reflecting the motivation of physicians for
research participation revealed that to facilitate physician par-
ticipation, the research topic should be in-line with their inter-
est, relevant and important to their field, linked to the real
world of clinical practice, and above all, should have clear
potential to improve patient care (Albers and Sedler 2004;
Armstrong et al. 2009; Duca et al. 2017). It is mentioned that
activities integrated into the usual patterns of patient care
which do not interfere with the flow of patient care increase
the likelihood of physician participation (Armstrong et al.
2009). Regular feedback and support along with financial
compensation as it is practiced in the Fr1da study will moti-
vate physicians to participate in clinical research (Yanos and
Ziedonis 2006; Rahman et al. 2011).
Patient satisfaction is an increasingly important measure in
health care delivery. Studies have demonstrated positive asso-
ciations between overall patient satisfaction and clinical out-
comes (Glickman et al. 2010). It has been shown that patient
satisfaction correlates highly with communication with nurses
and/or certified clinical research coordinators/assistants, who
represent the larger organization (Manary et al. 2013). In
terms of the Fr1da study this is reflected by the overall positive
judgement of the organization and care provided by primary
care pediatricians, pediatric diabetes expert centers and the
coordinating center. This leads to a general satisfaction with
the participation in the study. In addition, most parents were
satisfied with their decision to participate in the Fr1da screen-
ing, which indicates an acceptance of the Fr1da concept al-
though personal interviews with the families have shown that
the diagnosis of pre-symptomatic stage type 1 diabetes came
unexpectedly for most parents.
We conclude that the Fr1da study works so well because
primary care physicians, pediatric diabetes care centers and
families were well integrated into the whole concept of the
study and the medical community was convinced of a poten-
tial improvement of patient care.
As the educational training and medical care has been im-
plemented at multiple locations, a process evaluation is essen-
tial to ensure that the planned interventions are carried out
equally at all sites. Since our analysis demonstrated that the
majority of parents had a sustainable knowledge about impor-
tant aspects of type 1 diabetes care and potential complications
we assess the output of the educational training positively.
This could prevent severe metabolic decompensation.
Fig. 1 Evaluation of Fr1da study
by participating families six
months after educational training
(n = 170). The parents were asked
about their satisfaction of
different study aspects, the
percentage of each rating is
plotted
Fig. 2 Assessment of effectiveness of the educational training. Parents
were asked diabetes related questions one to two weeks (n = 157), six
(n = 156) and twelve (n = 114) months after the educational training, the
percentage of correct answers is plotted for each question
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